Efficacy News and Research

RSS

Efficacy of booster messenger ribonucleic acid COVID-19 vaccinations against SARS-CoV-2 Omicron variant severity

Researchers estimated the effectiveness of monovalent messenger ribonucleic acid (mRNA) coronavirus disease 2019 (COVID-19) vaccines against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Omicron variant of concern (VOC) infection severity outcomes among adults.

4 Nov 2022

Study evaluates BA.5-bivalent booster against new Omicron sublineages

In a new study, researchers evaluated the efficacy of four doses of parental messenger ribonucleic acid (mRNA) vaccine and a BA.5-bivalent booster against recently emerged Omicron sublineages. Additionally, they determined whether prior infection improved the effect of a booster vaccination.

4 Nov 2022

Specific mutations in the monkeypox virus contribute to its continued infectiousness

Monkeypox has infected more than 77,000 people in more than 100 countries worldwide, and - similar to COVID-19 - mutations have enabled the virus to grow stronger and smarter, evading antiviral drugs and vaccines in its mission to infect more people.

4 Nov 2022

Weekly weight loss drug reduces BMI in teens

Researchers report that a weekly dose of semaglutide led to a significant BMI reduction in adolescents.

3 Nov 2022

Novel monoclonal antibodies NA8 and NE12 can neutralize most SARS-CoV-2 variants and Omicron subvariants

Researchers generated and characterized two monoclonal antibodies (NA8 and NE12) that target the receptor binding domain of the SARS-CoV-2 spike protein, and exhibit neutralizing activity against major SARS-CoV-2 variants of concern.

3 Nov 2022

Study explores the potential use of anti-thymic stromal lymphopoietin monoclonal antibody as an adjuvant in allergic immunotherapy

A new study investigated the impact of a monoclonal anti-thymic stromal lymphopoietin (TSLP) antibody on subcutaneous allergen immunotherapy (SCIT) efficacy among patients with allergic rhinitis.

3 Nov 2022

A review of vaccines against the respiratory syncytial virus

This study reviewed the epidemiology, molecular characteristics, populations affected by the virus, and vaccines against RSV.

3 Nov 2022

Vaccination with senescent cells could be a possible therapy against cancer

Cancer cells have a series of features that allow the immune system to identify and attack them. However, these same cells create an environment that blocks immune cells and protects the tumor.

3 Nov 2022

Bivalent mRNA booster broadens humoral immunity against SARS-CoV-2 Omicron subvariants

Researchers at Emory University, Stanford University, and the National Institute of Allergy and Infectious Diseases evaluated whether bivalent coronavirus disease 2019 (COVID-19) boosters conferred protection against new Omicron subvariants.

2 Nov 2022

Scientists identify a broadly neutralizing antibody against all dominant SARS-CoV-2 variants

Researchers in the United States identified a broadly neutralizing antibody (S728-1157 bnAb) that targets the receptor-binding site (RBS) of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).

2 Nov 2022

Targeted therapy for children with high-risk Hodgkin lymphoma reduces relapse rates, trial shows

A targeted therapy for children with high-risk Hodgkin lymphoma (HL) was shown to significantly reduce relapse rates when tested in a large multicenter clinical trial conducted by the Children's Oncology Group (COG) and led by pediatric oncologists at Roswell Park Comprehensive Cancer Center, Children's Healthcare of Atlanta and Winship Cancer Institute of Emory University. By combining the targeted antibody-drug conjugate (ADC) brentuximab vedotin (BV) with the standard chemotherapy regimen, children were 10% less likely to relapse.

2 Nov 2022

RSV and kids: What you need to know

An overview on the prevalence, symptoms, and management of RSV in children.

2 Nov 2022

First-of-its-kind computer model simulates a clinical trial evaluating two Alzheimer’s drugs

An estimated 6.2 million Americans ages 65 and older are living with Alzheimer's disease. The national Alzheimer's Association predicts that number to grow to 13.8 million by 2060, barring the development of medical breakthroughs that would prevent, slow or cure the debilitating disease.

2 Nov 2022

Efficacy News and Research

Efficacy of booster messenger ribonucleic acid COVID-19 vaccinations against SARS-CoV-2 Omicron variant severity

Study evaluates BA.5-bivalent booster against new Omicron sublineages

Specific mutations in the monkeypox virus contribute to its continued infectiousness

Weekly weight loss drug reduces BMI in teens

Novel monoclonal antibodies NA8 and NE12 can neutralize most SARS-CoV-2 variants and Omicron subvariants

Study explores the potential use of anti-thymic stromal lymphopoietin monoclonal antibody as an adjuvant in allergic immunotherapy

A review of vaccines against the respiratory syncytial virus

Vaccination with senescent cells could be a possible therapy against cancer

Bivalent mRNA booster broadens humoral immunity against SARS-CoV-2 Omicron subvariants

Scientists identify a broadly neutralizing antibody against all dominant SARS-CoV-2 variants

Targeted therapy for children with high-risk Hodgkin lymphoma reduces relapse rates, trial shows

RSV and kids: What you need to know

First-of-its-kind computer model simulates a clinical trial evaluating two Alzheimer’s drugs

UC researchers receive NIH grant to study how alcohol, fentanyl affect HIV medications

Study identifies a new therapeutic strategy to tackle endometrial cancer

What is the role of cyclophilin-A in alleviating SARS-CoV-2 infections?

Effectiveness of prior infection in preventing reinfection with SARS-CoV-2 Omicron BA.2.75 sublineage

How does imprinted SARS-CoV-2 humoral immunity drive convergent Omicron evolution?

An optimal approach to treat femoropopliteal lesions

New research lays the foundation for more effectively treating pediatric brain tumor

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Latest News